Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, honours the passing of its founder, William J. (Bill)
Gastle, surrounded by family in Edmonton, Alberta on September 6,
2023.
Bill trained as a virologist and founded
Microbix in 1984. The Company began with the sale of bacterial and
cellular growth media to Canadian public health laboratories. It
was soon entrusted with culturing different pathogens of concern
for those labs and later with producing them as critical
ingredients for infectious disease test developers around the
world. Today, Microbix is a manufacturer of not only vital test
ingredients, but of a wide range of medical devices that help
ensure the accuracy of diagnostic tests.
Bill served as Microbix’s CEO for 28 years and
as a director for 36 years. Bill retired in October, 2020, after
which he and his wife Susan moved west to be closer to their son,
Angus, and his family.
Martin Marino, Independent Chairman of Microbix,
expressed condolences on behalf of the Board, “Bill was a
courageous entrepreneur who loved leading a team of talented people
in exploring new ideas and opportunities. I will remember him most
as a world-class advocate for the return of Kinlytic urokinase, a
life supporting thrombolytic drug. I have always believed that his
unwavering dedication to the Kinlytic project was based much more
on humanitarianism than financial reward, and that the world will
one day be blessed by this enduring legacy. Bill’s contributions to
Microbix are immeasurable and, alongside his family, we’ll sorely
miss his good cheer, wit, and intelligence.”
Cameron Groome, CEO and President of Microbix,
also commented on behalf of management and staff, “Beyond
excellence in science and innovation, Bill created a culture of
honesty, loyalty, and caring. His leadership and vision will live
on at Microbix, which remains an irreplaceable reservoir of
Canadian life sciences expertise and the longest-standing
locally-headquartered public company in this field.”
Everyone at Microbix wishes the best to the
Gastle family at this difficult time.
A service in memory of William J. (Bill) Gastle
will be held at the A.W. Mackenzie Chapel at Lakefield College
School, located at 4391 County Rd 29, Lakefield, Ontario on
Saturday, October 14th, 2023 at 2:00 pm EST with a reception
following the service.
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and annualized sales targeting C$ 2.0 million per month.
It makes a wide range of critical ingredients and devices for the
global diagnostics industry, notably antigens for immunoassays and
its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Its antigens drive the antibody tests of approximately
100 diagnostics makers, while QAPs are sold to clinical lab
accreditation organizations, diagnostics companies, and clinical
labs. Microbix QAPs are now available in over 30 countries,
supported by a network of 10 international distributors. Microbix
is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian
TGA registered, Health Canada establishment licensed, and provides
CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of Bill Gastle
and his accomplishments, Microbix’s or others’ products or
services, business and business results, goals or outlook, risks
associated with financial results and stability, development
projects such as those referenced in its presentations, regulatory
compliance and approvals, sales to foreign jurisdictions,
engineering and construction, production (including control over
costs, quality, quantity or timeliness of delivery), currency
exchange rates, maintaining adequate working capital or raising new
capital on acceptable terms or at all, and other similar statements
about anticipated future events, conditions or results that are not
historical facts. These statements reflect management’s current
estimates, beliefs, intentions, and expectations; they are not
guarantees of future performance. Microbix cautions that all
forward-looking information is inherently uncertain and actual
performance may be affected by a number of material factors, many
of which are beyond its control. Accordingly, actual future events,
conditions and results may differ materially from the estimates,
beliefs, intentions, and expectations expressed or implied in the
forward-looking information. All statements are made as of the date
of this news release and represent Microbix’s judgement as of the
date of this new release, and it is under no obligation to update
or alter any forward-looking information.
Please visit https://microbix.com or
www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome,CEO(905) 361-8910 |
Jim Currie,CFO(905) 361-8910 |
Deborah Honig,Investor RelationsAdelaide Capital Markets(647)
203-8793ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024